| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/16/1999 | CN1219872A Compositions and method for treating or preventing diseases of body passageways |
| 06/16/1999 | CN1219583A New technology for bifidobacteria culture and production of powder preparation |
| 06/15/1999 | US5912330 Sweeteners |
| 06/15/1999 | US5912322 Polypeptide with either deletions or substitions of cysteine residues; when fused with transforming growth factor-alpha protein has decreased killing activity and increased receptor-binding activity; anticarcinogenic agents |
| 06/15/1999 | US5912300 Stabilizing anionic oligonucleotide by complexing(ionic bonding) it with a cationic lysine-serine copolymer, for delivering drugs or genetically active materials to cell interiors where they release smoothly |
| 06/15/1999 | US5912271 Local anaesthetic agents, a polar lipid, a triacylglycerol and optionally water. |
| 06/15/1999 | US5912265 Administering silymarin, silybin, silidianin, silicristin, dehydrosilybin or mixtures; antitumor and anticarcinogenic agents |
| 06/15/1999 | US5912014 Oral salmon calcitonin pharmaceutical products |
| 06/15/1999 | US5912011 Solvent system to be enclosed in capsules |
| 06/15/1999 | US5912009 Fatty acid esters of glycolic acid and its salts |
| 06/15/1999 | US5912008 Laminated structure of backing layer, moisture and impermeable layer, tackifiers and permeation enhancer |
| 06/15/1999 | US5912007 Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
| 06/15/1999 | US5912000 Chitosan induced immunopotentiation |
| 06/15/1999 | US5911995 EGF-genistein conjugates for the treatment of cancer |
| 06/15/1999 | US5911972 Stable microbubbles suspensions injectable into living organisms |
| 06/15/1999 | US5911969 Pretargeting protocols for enhanced localization of active agents to target sites |
| 06/15/1999 | US5911966 High surface area alumina solid |
| 06/15/1999 | CA2201749C Stable aqueous alfa interferon solution formulations |
| 06/15/1999 | CA2161641C Stable, ingestable and absorbable nadh and nadph therapeutic compositions |
| 06/15/1999 | CA2128423C Health and beauty aid compositions |
| 06/10/1999 | WO1999028471A2 ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| 06/10/1999 | WO1999028345A1 Conjugates useful in the treatment of prostate cancer |
| 06/10/1999 | WO1999027983A1 A ONE DOSE SYRINGE, COMPRISING A FREEZE-DRIED PROTEIN COMPOSITION, FOR ADMINISTERING OF A VOLUME LESS THAN 0.5 ml |
| 06/10/1999 | WO1999027967A1 Therapeutic agents |
| 06/10/1999 | WO1999027966A1 Minoxidil-containing liquid preparation composition |
| 06/10/1999 | WO1999027961A1 Transdermal delivery of particulate vaccine compositions |
| 06/10/1999 | WO1999027960A1 Vaccine compositions for mucosal administration comprising chitosan |
| 06/10/1999 | WO1999027950A1 Compositions of leukaemia inhibitory factor |
| 06/10/1999 | WO1999027944A1 Prevention and treatment of amyloidogenic disease |
| 06/10/1999 | WO1999027940A1 Formulations for topical treatment of skin infections |
| 06/10/1999 | WO1999027932A1 Injectable antifungal formulations |
| 06/10/1999 | WO1999027916A2 Method for producing solid dosing forms |
| 06/10/1999 | WO1999027914A1 A pharmaceutical formulation of monoquaternary 2,16-bispiperidinylandrostane for intramuscular administration |
| 06/10/1999 | WO1999027913A1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 06/10/1999 | WO1999027912A1 Porous hydroxyapatite particles as carriers for drug substances |
| 06/10/1999 | WO1999027908A1 Combined chemo-immunotherapy with liposomal drugs and cytokines |
| 06/10/1999 | WO1999027907A1 Improved method for avoiding the degradation of an active principle |
| 06/10/1999 | WO1999027906A1 Long acting injectable formulations containing hydrogenated castor oil |
| 06/10/1999 | WO1999027905A1 Compositions for nasal administration |
| 06/10/1999 | WO1999027897A1 Site-specific preparation of polyethylene glycol-grf conjugates |
| 06/10/1999 | WO1999027801A1 Revitalisation formulation |
| 06/10/1999 | WO1999015156B1 Inhibition of crystallization in transdermal devices |
| 06/10/1999 | WO1999013095A3 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses |
| 06/10/1999 | WO1999012545A3 Medicaments containing acyclovir |
| 06/10/1999 | WO1999008684A3 Solutions containing azasteroids |
| 06/10/1999 | WO1999004765A3 Pharmaceutical compositions containing an effervescent acid-base couple |
| 06/10/1999 | DE19812413C1 Transdermal therapeutic system for administration of oxybutynin |
| 06/10/1999 | CA2313029A1 Improved method for avoiding the degradation of an active principle |
| 06/10/1999 | CA2312920A1 Prevention and treatment of amyloidogenic disease |
| 06/10/1999 | CA2312900A1 Transdermal delivery of particulate vaccine compositions |
| 06/10/1999 | CA2312778A1 Combined chemo-immunotherapy with liposomal drugs and cytokines |
| 06/10/1999 | CA2311930A1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 06/10/1999 | CA2311780A1 Porous hydroxyapatite particles as carriers for drug substances |
| 06/10/1999 | CA2311731A1 Minoxidil-containing liquid preparation composition |
| 06/10/1999 | CA2311633A1 Compositions of leukaemia inhibitory factor |
| 06/10/1999 | CA2311615A1 Conjugates useful in the treatment of prostate cancer |
| 06/10/1999 | CA2310718A1 Vaccine compositions for mucosal administration comprising chitosan |
| 06/09/1999 | EP0920873A2 Stabilized teriparatide solutions |
| 06/09/1999 | EP0920869A1 Stable aspirin-containing preparations for external use |
| 06/09/1999 | EP0920623A1 Boron neutron capture therapy using pre-targeting methods |
| 06/09/1999 | EP0920510A1 GnRH-LEUKOTOXIN CHIMERAS |
| 06/09/1999 | EP0920467A1 Hydrophilic and hydrophobic polyether polyurethanes and uses therefor |
| 06/09/1999 | EP0920339A2 Gene delivery system |
| 06/09/1999 | EP0920338A2 Composition for pharmaceutical applications |
| 06/09/1999 | EP0920337A1 Use of inorganic aerogels in pharmacy |
| 06/09/1999 | EP0920328A1 Allogeneic histocompatibility complexes as mediators of cell destruction |
| 06/09/1999 | EP0920320A2 Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol |
| 06/09/1999 | EP0920311A1 Parenteral paclitaxel in a stable non-toxic formulation |
| 06/09/1999 | EP0920302A1 Pharmaceutical aerosol composition |
| 06/09/1999 | EP0828482A4 Cosmetic make-up compositions |
| 06/09/1999 | EP0799035A4 Emulsion suitable for administering a sphingolipid and use thereof |
| 06/09/1999 | EP0752855B1 Use of fatty acid esters as bioadhesive substances |
| 06/09/1999 | EP0721327B1 Aerosol composition for forming a preferably hydrated membrane, preferably hydrated membrane so obtained, and applications thereofparticularly as a dressing |
| 06/09/1999 | EP0713390B1 Gelatin capsules containing a highly concentrated acetaminophen solution |
| 06/09/1999 | EP0620740B1 Injectable lecithin gel |
| 06/09/1999 | CN1218806A Sorbic acid vitamin C ester |
| 06/09/1999 | CN1218663A Use of 2'-ascorbate phosphate for stabilizing vitamin A and/or vitamin A derivative in cosmetic and modicinal preparation |
| 06/08/1999 | US5910512 Capsaicin, magnesium oxide, disodium edta and water; no harsh solvents, gentle to skin; treating rheumatoid arthritis, muscle pain |
| 06/08/1999 | US5910492 Osteogenic promoting pharmaceutical composition |
| 06/08/1999 | US5910489 Treating skin diseases such as cancer, liver spots, genital warts, by topically applying a penetrating formulation of hyaluronic acid and/or salts and an agent to treat the skin such as a nonsteroidal antiinflammatory drug |
| 06/08/1999 | US5910488 Plasmids suitable for gene therapy |
| 06/08/1999 | US5910487 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| 06/08/1999 | US5910319 Superior single dose formulation of the antidepressant drug, layer comprising hydroxypropylmethylcellulose acetate succinates |
| 06/08/1999 | US5910318 Complexing elemental iodine with amylose to treat breast dysplasia, breast cancer, endometriosis, premenstrual syndrome, ovarian cysts and radiation sickness, oral administration of pill or capsule |
| 06/08/1999 | US5910316 Concentrated and localized release of no at a given site in a controllable and predictable manner such that effective dosing can be realized |
| 06/08/1999 | US5910311 Inhibiting photoperoxidation of unsaturated lipid by contacting with composition comprising non-photocatalytic metal oxide, tocopherol, metal-inactivating complexing agent |
| 06/08/1999 | US5910301 Method of intrapulmonary administration of a narcotic drug |
| 06/08/1999 | US5910300 Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds |
| 06/08/1999 | CA2151012C Surfactantless water-in-oil emulsion |
| 06/08/1999 | CA2136946C Oral decongestant product |
| 06/03/1999 | WO1999027102A1 Cd4+ t-lymphocyte protease genes and inhibitors thereof |
| 06/03/1999 | WO1999027071A1 Preservation of sensitive biological samples by vitrification |
| 06/03/1999 | WO1999026971A1 Antimicrobial peptides |
| 06/03/1999 | WO1999026965A1 Cyclosporine derivatives and uses thereof |
| 06/03/1999 | WO1999026954A1 Mitochondrially targeted antioxidants |
| 06/03/1999 | WO1999026661A1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
| 06/03/1999 | WO1999026660A2 Conjugates of cytokines and drugs or genes for treating proliferating cells |
| 06/03/1999 | WO1999026652A1 Mucosal delivery system comprising lipophilic thrombin inhibitors |
| 06/03/1999 | WO1999026626A1 Spheroids containing tiagabine, preparation process and pharmaceutical compositions |
| 06/03/1999 | WO1999026620A1 Choline esters of fatty acids and their use in the treatment of stroke |